Guggenheim analyst Subbu Nambi raised the firm’s price target on Guardant Health (GH) to $56 from $49 and keeps a Buy rating on the shares. Reported Q4 revenues were in-line with the recent pre-announcement and the company’s FY25 guidance “appears reasonable, with many opportunities for upside,” the analyst tells investors.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GH:
- Guardant Health’s Promising Growth Prospects: Buy Rating Backed by Strong Revenue Guidance and Optimistic Projections
- Guardant Health’s Strong 2024 Growth and 2025 Outlook
- Guardant Health: Strong Buy Rating Driven by Surpassing Performance and Optimistic Growth Outlook
- Guardant Health options imply 9.3% move in share price post-earnings
- GH Earnings Report this Week: Is It a Buy, Ahead of Earnings?